bexarotene has been researched along with Cancer of Head in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ba'th, F; Handley, N; Mathison, G; Nachbor, KM; Ondrey, FG; Rosas, RR; Wuertz, BR | 1 |
| Climent, J; Estrach, T; Gallardo, F; Garcia-Muret, P; Muniesa, C; Pujol, RM; Servitje, O | 1 |
| Chang, WC; Clapper, ML; Fischer, SM; Grubbs, CJ; Juliana, MM; Lubet, RA; McCormick, DL; Pereira, MA; Steele, VE | 1 |
| Grandis, JR; Johnson, DE; Lamph, WW; Lango, M; Miller, L; Song, JI; Wentzel, AL; Xi, S | 1 |
| Biddle, A; Desai, NB; Dmitrovsky, E; Dragnev, KH; Memoli, V; Petty, WJ; Rigas, JR; Shah, S | 1 |
| Drenning, SD; Grandis, JR; Hwang, JD; Lamph, WW; Lango, MN; Song, JI; Zeng, Q | 1 |
1 trial(s) available for bexarotene and Cancer of Head
| Article | Year |
|---|---|
Bexarotene and erlotinib for aerodigestive tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cyclin D1; Digestive System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 2005 |
5 other study(ies) available for bexarotene and Cancer of Head
| Article | Year |
|---|---|
Preclinical evidence for pioglitazone and bexarotene combination in oral cancer chemoprevention.
Topics: Bexarotene; Chemoprevention; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Pioglitazone; United States | 2022 |
Folliculotropic mycosis fungoides: clinicopathological features and outcome in a series of 20 cases.
Topics: Adult; Aged; Aged, 80 and over; Bexarotene; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mycosis Fungoides; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome | 2010 |
Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Bexarotene; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Female; Head and Neck Neoplasms; Intestinal Neoplasms; Male; Mammary Neoplasms, Animal; Mice; Mice, Knockout; Neoplasms; Pyrazoles; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Sulfonamides; Tetrahydronaphthalenes; Urinary Bladder Neoplasms | 2012 |
Responsiveness to the retinoic acid receptor-selective retinoid LGD1550 correlates with abrogation of transforming growth factor alpha/epidermal growth factor receptor autocrine signaling in head and neck squamous carcinoma cells.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Bexarotene; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; ErbB Receptors; Fatty Acids, Unsaturated; Head and Neck Neoplasms; Humans; Receptors, Retinoic Acid; Retinoids; Signal Transduction; Tetrahydronaphthalenes; Transplantation, Heterologous | 2003 |
Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Division; DNA-Binding Proteins; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Receptors, Retinoic Acid; Retinoid X Receptors; Signal Transduction; STAT3 Transcription Factor; Tetrahydronaphthalenes; Trans-Activators; Transcription Factors; Transforming Growth Factor alpha; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |